111 related articles for article (PubMed ID: 28103781)
1. Prospective Clinical Applications of CRF Peptide Antagonists.
Rivier JE
Curr Mol Pharmacol; 2017; 10(4):264-269. PubMed ID: 28103781
[TBL] [Abstract][Full Text] [Related]
2. Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance.
Rivier JE; Rivier CL
Front Neuroendocrinol; 2014 Apr; 35(2):161-70. PubMed ID: 24269930
[TBL] [Abstract][Full Text] [Related]
3. Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photoaffinity labeling studies on CRF receptor, type 1 (CRFR1).
Bonk I; Rühmann A
Eur J Biochem; 2000 May; 267(10):3017-24. PubMed ID: 10806401
[TBL] [Abstract][Full Text] [Related]
4. CRF1 receptors as a therapeutic target for irritable bowel syndrome.
Martinez V; Taché Y
Curr Pharm Des; 2006; 12(31):4071-88. PubMed ID: 17100612
[TBL] [Abstract][Full Text] [Related]
5. Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.
Fahmy H; Kuppast B; Ismail MT
Curr Mol Pharmacol; 2017; 10(4):270-281. PubMed ID: 27809751
[TBL] [Abstract][Full Text] [Related]
6. Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
J Endocrinol; 2018 Nov; 239(2):241-252. PubMed ID: 30139928
[TBL] [Abstract][Full Text] [Related]
7. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
[TBL] [Abstract][Full Text] [Related]
8. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists.
Eckart K; Jahn O; Radulovic J; Tezval H; van Werven L; Spiess J
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11142-7. PubMed ID: 11572971
[TBL] [Abstract][Full Text] [Related]
9. Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome.
Nozu T; Okumura T
J Gastroenterol; 2015 Aug; 50(8):819-30. PubMed ID: 25962711
[TBL] [Abstract][Full Text] [Related]
10. Progress in corticotropin-releasing factor-1 antagonist development.
Zorrilla EP; Koob GF
Drug Discov Today; 2010 May; 15(9-10):371-83. PubMed ID: 20206287
[TBL] [Abstract][Full Text] [Related]
11. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
McCarthy JR; Heinrichs SC; Grigoriadis DE
Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
[TBL] [Abstract][Full Text] [Related]
12. From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases.
Taché Y; Brunnhuber S
Ann N Y Acad Sci; 2008 Dec; 1148():29-41. PubMed ID: 19120089
[TBL] [Abstract][Full Text] [Related]
13. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
[TBL] [Abstract][Full Text] [Related]
15. Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome.
Taché Y; Martinez V; Million M; Maillot C
Eur J Surg Suppl; 2002; (587):16-22. PubMed ID: 16144197
[TBL] [Abstract][Full Text] [Related]
16. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat.
Rivier J; Gulyas J; Corrigan A; Martinez V; Craig AG; Taché Y; Vale W; Rivier C
J Med Chem; 1998 Dec; 41(25):5012-9. PubMed ID: 9836619
[TBL] [Abstract][Full Text] [Related]
17. Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
J Gastroenterol; 2017 Jan; 52(1):72-80. PubMed ID: 27075754
[TBL] [Abstract][Full Text] [Related]
18. Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.
Jahn O; Tezval H; van Werven L; Eckart K; Spiess J
Neuropharmacology; 2004 Aug; 47(2):233-42. PubMed ID: 15223302
[TBL] [Abstract][Full Text] [Related]
19. Corticotropin-releasing factor receptor 1 (CRF-R1) antagonists: Promising agents to prevent visceral hypersensitivity in irritable bowel syndrome.
Lv Y; Wen J; Fang Y; Zhang H; Zhang J
Peptides; 2022 Jan; 147():170705. PubMed ID: 34822913
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and chemical properties of astressin, antisauvagine-30 and alpha-helCRF: significance for behavioral experiments.
Brauns O; Liepold T; Radulovic J; Spiess J
Neuropharmacology; 2001 Sep; 41(4):507-16. PubMed ID: 11543771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
